SCHEMBL30228381

SCHEMBL30228381

Cc1ccccc1-c1cc(=O)oc2cc(CN)ccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNA3 P22001 4/20 0.56
▸ CA9 Q16790 7/20 0.49
▸ CA1 P00915 3/20 0.49
▸ CA2 P00918 2/20 0.49
▸ CA5A P35218 2/20 0.49
▸ CA12 O43570 6/20 0.46
▸ ALDH1A1 P00352 4/20 0.44
▸ LMNA P02545 2/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ KDM4E B2RXH2 2/20 0.43
▸ GAA P10253 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ GLA P06280 1/20 0.43
▸ CASP1 P29466 1/20 0.43
▸ CASP7 P55210 1/20 0.43
▸ CA3 P07451 1/20 0.43
▸ CA4 P22748 1/20 0.43
▸ CA6 P23280 1/20 0.43
▸ CA7 P43166 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30228355 0.99 KCNA3 (0.55) KCNA3CA9CA1CA2CA5A
SCHEMBL30228517 0.86 KCNA3 (0.54) KCNA3CA9CA1CA2CA5A
SCHEMBL30227920 0.85 KCNA3 (0.53) KCNA3CA9CA1CA2CA5A
SCHEMBL30228231 0.85 KCNA3 (0.53) KCNA3CA9CA1CA2CA5A
SCHEMBL31710481 0.84 KCNA3 (0.52) KCNA3CA9CA12ALDH1A1LMNA
SCHEMBL30228337 0.83 CA12 (0.65) KCNA3CA9CA1CA12ALDH1A1
SCHEMBL30228338 0.82 KCNA3 (0.50) KCNA3CA9CA12ALDH1A1KDM4E
SCHEMBL30228319 0.82 KCNA3 (0.47) KCNA3CA9CA1CA2CA5A
SCHEMBL30228412 0.81 KCNA3 (0.62) KCNA3CA9CA1CA12ALDH1A1
SCHEMBL5691199 0.81 KCNA3 (0.62) KCNA3CA9CA1CA12ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326732-A1 CHROMEN-2-ONE MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-10-23 — — US disclosed
WO-2023034346-A1 CHROMEN-2-ONE MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2023-03-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326732-A1 CHROMEN-2-ONE MODULATORS OF POLRMT POLRMT, TFAM, POLM KCNA3 4258/4885CA9 4824/4885CA1 4860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback